Unity Biotechnology (NASDAQ:UBX) Stock Rating Reaffirmed by Wedbush

Unity Biotechnology (NASDAQ:UBX – Get Rating)‘s stock had its “outperform” rating reissued by analysts at Wedbush in a research report issued on Thursday, Benzinga reports. They currently have a $35.00 price target on the stock.

UBX has been the topic of a number of other reports. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Unity Biotechnology in a research note on Wednesday, February 15th. Mizuho dropped their price objective on shares of Unity Biotechnology from $80.00 to $12.00 and set a “buy” rating on the stock in a research note on Wednesday, November 16th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $34.25.

Unity Biotechnology Price Performance

Shares of UBX opened at $3.78 on Thursday. Unity Biotechnology has a 1-year low of $2.09 and a 1-year high of $18.50. The stock has a market cap of $53.64 million, a PE ratio of -0.52 and a beta of 0.79. The company has a debt-to-equity ratio of 0.17, a current ratio of 6.12 and a quick ratio of 6.12. The firm has a fifty day moving average price of $4.30 and a 200 day moving average price of $3.87.

Institutional Trading of Unity Biotechnology

Institutional investors and hedge funds have recently modified their holdings of the business. UBS Oconnor LLC purchased a new position in shares of Unity Biotechnology during the third quarter valued at approximately $240,000. Parkman Healthcare Partners LLC purchased a new position in shares of Unity Biotechnology during the third quarter valued at approximately $160,000. Arete Wealth Advisors LLC purchased a new position in shares of Unity Biotechnology during the fourth quarter valued at approximately $140,582,970,000. Mayo Clinic purchased a new position in shares of Unity Biotechnology during the fourth quarter valued at approximately $431,000. Finally, Maven Securities LTD purchased a new position in shares of Unity Biotechnology during the third quarter valued at approximately $40,000.

About Unity Biotechnology

(Get Rating)

Unity Biotechnology, Inc operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in South San Francisco, CA.